Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Passage BioPASG +1.08%30 Interest Coverage is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 373 Biotechnology companies, Passage Bio ranks worse than 268096.25% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Passage Bio's
Operating Income
for the
three
months ended in Jun. 2026 was $-10.22 Mil. Passage Bio's Interest Expense for the
three
months ended in Jun. 2026 was $0.00 Mil.
Passage Bio has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Passage Bio Inc has enough cash to cover all of its debt. Its financial situation is stable.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Passage Bio's Interest Coverage or its related term are showing as below:
PASG's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 99.7 * Ranked among companies with meaningful Interest Coverage only.
Passage Bio (NAS:PASG) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Passage Bio Interest Coverage Related Terms
Passage Bio Interest Coverage Historical Data
* Premium members only.
The historical data trend for Passage Bio's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
PASG vs OTLC, KTTA, LSTA: Interest Coverage Comparison
For the Biotechnology subindustry, Passage Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Passage Bio Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Passage Bio's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Passage Bio's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Passage Bio (PASG) has a Interest Coverage of No Debt (1) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Passage Bio and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Passage Bio's Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Passage Bio ranks #999999 out of 373 companies in the Biotechnology industry.
Is Passage Bio's Interest Coverage too high?
Passage Bio's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Passage Bio ranks #999999 out of 373 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Interest Coverage compare to OTLC and KTTA?
According to the Biotechnology industry distribution chart, Passage Bio ranks #999999 out of 373 companies for Interest Coverage. This places Passage Bio in the lower half of its industry. The industry median Interest Coverage is 99.70. Historically, Passage Bio's own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 99.70, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Passage Bio and its competitors. For the Biotechnology industry, the median Interest Coverage is 99.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Passage Bio (PASG), the current Interest Coverage is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score
Get the complete analysis for PASG
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASG has been successfully added to your 
